New Blood Test Heralds Breakthrough in Preterm Birth Prevention

AUSTIN, TX – March 11, 2026 – A groundbreaking national study, with a Central Texas hospital playing a pivotal role, has demonstrated that a simple blood test can identify previously hidden risks for preterm birth, leading to interventions that significantly improve outcomes for newborns. The findings, from the PRIME clinical trial, could fundamentally change how prenatal care is administered, offering a new weapon in the fight against a leading cause of infant mortality and long-term disability.

St. David's Women's Center of Texas was one of only 19 sites nationwide—and the highest-enrolling site in Texas—to participate in the study. The research focused on a population often overlooked by traditional screening: pregnant individuals considered low risk. The results suggest a new era of proactive, personalized care is on the horizon for expectant parents.

Redefining 'Low Risk' in Pregnancy

For decades, the medical community has struggled to predict and prevent preterm birth, defined as birth before 37 weeks of gestation. While known risk factors like a previous preterm birth or carrying multiples can flag some patients for closer monitoring, a large percentage of premature deliveries occur in women with no apparent risks. This has been a frustrating and dangerous gap in prenatal care.

The PRIME (Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes) study was designed to address this very gap. The trial, which involved over 5,000 participants, used a maternal biomarker blood test between 18 and 21 weeks of pregnancy to assess the risk of spontaneous preterm birth. The test, commercially known as the PreTRM Test, measures the ratio of two proteins in the mother's blood: insulin-like growth factor–binding protein 4 and sex hormone–binding globulin (IGFBP4:SHBG).

"This study offered us an opportunity to participate in research that explored how we might better support patients whose risk for preterm birth may not be detected using traditional methods," said Dr. Mollie McDonnold, a maternal-fetal medicine specialist at Austin Maternal Fetal Medicine and the principal investigator at the St. David's site. "The patients we enrolled helped contribute to findings that could shape how maternal care is delivered nationwide."

Participants identified by the test as having a higher risk were placed on a proactive care regimen. This intervention bundle included daily vaginal progesterone, low-dose aspirin, and weekly telephonic check-ins with a nurse, all in addition to their standard prenatal care. Those who tested as lower risk continued with routine care, providing a clear comparison group.

Landmark Findings Offer New Hope

The results of the PRIME study, published in the January 2026 issue of Pregnancy, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, are striking. The data was so compelling that the trial was halted early for efficacy in December 2023, after a monitoring board determined its primary goals had been met.

The screen-guided care strategy led to statistically significant improvements across several critical measures. Compared to the routine care group, the intervention arm saw:
* A 20% reduction in the odds of composite neonatal morbidity and mortality.
* A 56% reduction in babies born very prematurely, before 32 weeks.
* A 32% reduction in babies born before 35 weeks.
* A 20% decrease in admissions to the neonatal intensive care unit (NICU).

Furthermore, when NICU admission was necessary, the length of stay was shorter for infants in the intervention group. The study demonstrated remarkable efficiency, calculating that for every 4.2 patients screened with the test-and-treat strategy, one full day in the NICU was saved. This "Number Needed to Screen" is a powerful metric that highlights the potential for both improved health outcomes and significant cost savings for the healthcare system.

Texas at the Forefront of Maternal Health Innovation

St. David's Women's Center of Texas, located at the St. David's North Austin Medical Center campus, distinguished itself as a leader in this national effort. As the highest-enrolling site in Texas and one of only two in the state, the center underscored the region's commitment to advancing maternal-fetal medicine.

The center's robust infrastructure, including a Level III NICU, a dedicated perinatal research division, and collaborations with national health organizations like the National Institutes of Health, made it an ideal partner for a complex trial like PRIME. This participation is part of a broader commitment to research that includes studies on twin pregnancies, birth outcomes, and other critical areas of women's health.

"We are proud to have taken part in this important work," Dr. McDonnold stated in the original announcement. The center's ability to successfully recruit and manage a large number of participants was crucial to the overall success of the study, positioning Austin as a key hub for clinical research in maternal health. This leadership role is further cemented by ongoing investments, such as a recent $38 million expansion to its NICU, ensuring the capacity to care for the region's most vulnerable newborns.

The Path to a New Standard of Care

The success of the PRIME study and the PreTRM Test, developed by health diagnostics company Sera Prognostics, Inc., paves the way for a potential paradigm shift in prenatal care. By providing an individualized risk assessment early in the second trimester, the test allows clinicians to move from a reactive to a proactive stance, targeting interventions to those who need them most, even if they don't fit traditional high-risk profiles.

The implications extend far beyond the clinic. Preterm birth is a leading driver of healthcare costs in the United States, with the March of Dimes reporting that one in ten infants is born prematurely. These births are associated with a lifetime of potential health challenges, including learning disabilities, cerebral palsy, and chronic illness, creating significant emotional and financial burdens for families.

With the study's robust findings now public, the path to broader clinical adoption is becoming clearer. Sera Prognostics is actively engaging with commercial insurers and state Medicaid programs to secure coverage for the test, aiming to make this predictive technology accessible to all pregnant individuals, regardless of their background. The study's diverse participant pool, which showed no significant demographic differences between the treatment and control arms, suggests the benefits could be applied equitably across the population. This research represents a major step forward, offering a tangible strategy to improve the health of mothers and babies and potentially alter the trajectory of countless lives for the better.